

Clinical trial results:

A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolescents with Oral Corticosteroid dependent Asthma (TROPOS) Summary

Results information	
Trial information	
Trial identification	
Additional study identifiers	
Sponsors	
Paediatric regulatory details	

Results analysis stage			
General information about the tri	ial		
	<u> </u>		
Population of trial subjects			
Subjects enrolled per country			
Subjects enrolled per age group			
, , , , , , , , , , , , , , , , , , , ,			

_	

Subject disposition		
Recruitment		
Pre-assignment		
assignment		
Period 1	Γ	
Arms		
Arm title		
Arm title		
	•	

Number of subjects in period 1	

Reporting groups Reporting group values

Baseline characteristics

	Γ			
Secondary: The number of patier Week 40.	its with final	daily average	e OCS dose ≤!	5 mg at
	1	1	i	1
End point values				
Statistical analyses				
Statistical analyses	 			
Statistical analysis title				
	<u> </u>			

	1			
	•			
Secondary: The number of patier dose at Week 40.	nts with ≥50%	% reduction i	n final averag	ge daily OCS
	•			
	-			
End noint values			T	<u> </u>
End point values				
Statistical analyses				
Statistical analysis title				
	L			


	I			
Secondary: Annual asthma exace	rbation rate	(AAER) up to	Week 40.	
	Ι			
	<u> </u>			
L	Ι			Γ
End point values				
Statistical analyses				
Statistical analysis title				
	1			
	l			

-	
	T
-	
	<u>L</u>

Adverse events information Dictionary used Reporting groups Serious adverse events

Adverse events

1	I	I	
	<u> </u>	<u> </u>	<u> </u>
 	1	 	
	1	·	
	i	1	i
Non-serious adverse events			



More information

Interruptions (globally)

Substantial protocol amendments (globally)

Date	Amendment

